Dsred Vsv Spike Protein
Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78637-1 | BPS Bioscience | 100 µl | EUR 795 |
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices. |
Human IgG antibody Laboratories manufactures the dsred vsv spike protein reagents distributed by Genprice. The Dsred Vsv Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Dsred products are available in stock. Specificity: Dsred Category: Vsv Group: Spike Protein
VSV-G-tag Antibody |
||
SAB | 100ul | EUR 399.6 |
VSV-G-tag Antibody |
||
SAB | 50ul | EUR 286.8 |
VSV-g Tag Antibody |
||
SAB | 100ul | EUR 399.6 |
VSV-g Tag Antibody |
||
SAB | 50ul | EUR 286.8 |
VSV- G tag Antibody |
||
Lifescience Market | 100 ug | EUR 525.6 |
VSV-G tag Antibody |
||
Abbexa | 100 ug | EUR 385.2 |
VSV-G-Tag Antibody |
||
Abbexa |
|
|
Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78640-1 | BPS Bioscience | 100 µl | EUR 795 |
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N |
Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78640-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N |
COVID-19 Spike Protein a.a. 1000-12000 |
|||
00223-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike Protein a.a. 1000-12000 |
Recombinant SARS Spike gp C Protein |
|||
VAng-Lsx0072-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS Spike glycoprotein C, recombinant protein from E. coli. |
Anti-MERSC-CoV Spike Protein antibody |
|||
STJ140102 | St John's Laboratory | 150 µg | EUR 277.2 |
Description: Goat polyclonal to Spike protein of Middle East respiratory Syndrome coronavirus. Coronaviruses access host cells by membrane fusion, a process mediated by specific fusion or “spike” proteins on the virion, often activated by cellular proteases. |
MERS-CoV Spike protein (aa 383-502) [Fc] |
|||
DAG-H10297 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike protein (aa 367-606) [Fc] |
|||
DAG-H10302 | Creative Diagnostics | 20µg | EUR 868.8 |
COVID-19 Spike Protein a.a. 800 to 1000 |
|||
00222-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike Protein a.a. 800 to 1000 |
MERS-CoV Spike protein (aa 1-1297) [His] |
|||
DAG-H10300 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike Protein (aa 367-606) [His] |
|||
DAGB201 | Creative Diagnostics | 20 µg | EUR 868.8 |
MERS Spike S1 Recombinant protein |
|||
39-102 | ProSci | 0.1 mg | EUR 556.8 |
Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis. |
Recombinant SARS Spike Protein (aa 1-1190) [His] |
|||
VAng-Lsx0063-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS Spike protein (aa 1-1190) [His], recombinant protein from HEK 293 cells. |
COVID-19 Spike S1 protein a.a. 1 to 800 |
|||
00226-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike S1 protein a.a. 1 to 800 |
MERS-CoV Spike protein S2 (aa 726-1296) [His] |
|||
DAG-H10296 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike protein S1 (aa 1-725) [His] |
|||
DAG-H10298 | Creative Diagnostics | 20µg | EUR 868.8 |
MERS-CoV Spike protein S1 (aa 1-725) [His] |
|||
DAG-H10301 | Creative Diagnostics | 20µg | EUR 868.8 |
SARS Spike RBD Recombinant Protein |
|||
10-211 | ProSci | 0.1 mg | EUR 651.3 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |